[1]赖全友,高 远,王尚毓,等.MRI联合血清赖氨酸氧化酶样蛋白4、信号转导和转录激活因子3检测用于原发性肝癌诊断的价值[J].陕西医学杂志,2024,(10):1398-1401,1406.[doi:DOI:10.3969/j.issn.1000-7377.2024.10.022]
　LAI Quanyou,GAO Yuan,WANG Shangyu,et al.Value of MRI combined with serum LOXL4 and STAT3 levels detection in diagnosis of primary liver cancer[J].,2024,(10):1398-1401,1406.[doi:DOI:10.3969/j.issn.1000-7377.2024.10.022]
点击复制

MRI联合血清赖氨酸氧化酶样蛋白4、信号转导和转录激活因子3检测用于原发性肝癌诊断的价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年10期
页码:
1398-1401,1406
栏目:
临床检验
出版日期:
2024-10-05

文章信息/Info

Title:
Value of MRI combined with serum LOXL4 and STAT3 levels detection in diagnosis of primary liver cancer
作者:
赖全友; 高 远; 王尚毓; 彭 伟
(空军军医大学第一附属医院肝胆胰脾外科,陕西 西安710032)
Author(s):
LAI Quanyou; GAO Yuan; WANG Shangyu; PENG Wei
(Department of Hepatobiliary Pancreaticosplenic Surgery,the First Affiliated Hospital of Air Force Medical University,Xi'an 710032,China)
关键词:
磁共振成像;  赖氨酸氧化酶样蛋白4;  信号转导和转录激活因子3;  原发性肝癌;  预测模型;  诊断价值
Keywords:
Magnetic resonance imaging;  Lysine oxidase like protein 4;  Signal transduction and transcriptional activation factor 3;  Primary liver cancer;  Prediction model;  Diagnostic value
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2024.10.022
文献标志码:
A
摘要:
目的:探讨磁共振成像(MRI)联合血清赖氨酸氧化酶样蛋白4(LOXL4)、信号转导和转录激活因子3(STAT3)检测用于原发性肝癌诊断的价值。方法:选取肝占位性病变患者214例,比较分析原发性肝癌和肝脏良性病变患者血清LOXL4、STAT3水平差异,以及原发性肝癌不同患者间差异,同时分析MRI联合血清LOXL4、STAT3水平诊断原发性肝癌的价值。结果:确诊为原发性肝癌患者92例,肝脏良性病变122例。原发性肝癌患者血清LOXL4、STAT3明显高于肝脏良性病变患者(均P<0.05)。TNM分期Ⅲ-Ⅳ患者血清LOXL4、STAT3明显高于肝脏良性病变患者(均P<0.05)。低分化患者血清LOXL4、STAT3明显高于中高分化患者(均P<0.05)。血清LOXL4、STAT3水平诊断原发性肝癌的ROC曲线下面积分别为0.890和0.896(均P<0.05)。MRI联合血清LOXL4、STAT3水平诊断原发性肝癌的灵敏性和阴性预测值分别为95.65%和96.00%,高于MRI检查(均P<0.05)。结论:原发性肝癌患者血清LOXL4、STAT3水平升高,与TNM分期及分化程度有关; MRI联合血清LOXL4、STAT3检测诊断原发性肝癌有较好的应用价值。
Abstract:
Objective:To explore the value of magnetic resonance imaging(MRI)combined with serum levels of lysine oxidase like protein 4(LOXL4)and signal transduction and transcriptional activation factor 3(STAT3)in the diagnosis of primary liver cancer.Methods:A total of 214 patients with liver space occupying lesions were selected,the differences in serum LOXL4 and STAT3 levels between patients with primary liver cancer and those with benign liver lesions were compared and analyzed,as well as the differences between different patients with primary liver cancer.At the same time,the value of MRI combined with serum LOXL4 and STAT3 levels in diagnosing primary liver cancer were analyzed.Results:There were 92 patients diagnosed with primary liver cancer and 122 cases with benign liver lesions.The serum levels of LOXL4 and STAT3 in patients with primary liver cancer were significantly higher than those in patients with benign liver lesions(all P<0.05).The serum levels of LOXL4 and STAT3 in TNM stage Ⅲ to Ⅳ patients were significantly higher than those in patients with benign liver lesions(all P<0.05).The serum levels of LOXL4 and STAT3 in patients with low differentiation were significantly higher than those in patients with medium to high differentiation(all P<0.05).The areas under the ROC curve for diagnosing primary liver cancer with serum LOXL4 and STAT3 levels were 0.890 and 0.896,respectively,and the sensitivity and negative predictive values of MRI combined with serum LOXL4 and STAT3 levels in diagnosing primary liver cancer were 95.65% and 96.00% respectively,which were higher than those of MRI examination(all P<0.05).Conclusion:The elevated levels of serum LOXL4 and STAT3 in patients with primary liver cancer are related to TNM staging and differentiation degree.The combination of MRI and serum levels of LOXL4 and STAT3 has good application value in the diagnosis of primary liver cancer.

参考文献/References:

[1] 郭桓博,马瑞雪,朱正望,等.中药基于铁死亡机制防治肝癌研究进展[J].陕西中医,2024,45(2):282-285.
[2] RUMGAY H,FERLAY J,DE MARTEL C,et al.Global,regional and national burden of primary liver cancer by subtype[J].Eur J Cancer,2022,161:108-118.
[3] MACIAS R I R,MONTE M J,SERRANO M A,et al.Impact of aging on primary liver cancer:Epidemiology,pathogenesis and therapeutics[J].Aging(Albany NY),2021,13(19):23416-23434.
[4] 孔庆旭,陈桂云,陈自力,等.槲芪方加减对肝癌化疗栓塞术后大鼠一氧化氮合酶、血管内皮生长因子、乏氧及免疫功能的影响[J].陕西中医,2024,45(2):181-186.
[5] CHANG J I,SINN D H,JEONG W K,et al.Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development[J].Scand J Gastroenterol,2022,57(12):1470-1477.
[6] TAN H Y,WANG N,ZHANG C,et al.Lysyl oxidase-like 4 fosters an immunosuppressive microenvironment during hepatocarcinogenesis[J].Hepatology,2021,73(6):2326-2341.
[7] ZOU S,TONG Q,LIU B,et al.Targeting STAT3 in cancer immunotherapy[J].Mol Cancer,2020,19(1):145.
[8] LIU Y,XU Q,DENG F,et al.HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway[J].J Exp Clin Cancer Res,2023,42(1):38.
[9] YANG J D,HAINAUT P,GORES G J,et al.A global view of hepatocellular carcinoma:Trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604.
[10] WEN N,CAI Y,LI F,et al.The clinical management of hepatocellular carcinoma worldwide:A concise review and comparison of current guidelines:2022 update[J].Biosci Trends,2022,16(1):20-30.
[11] WANG Z,QIN H,LIU S,et al.Precision diagnosis of hepatocellular carcinoma[J].Chin Med J(Engl),2023,136(10):1155-1165.
[12] PINERO F,DIRCHWOLF M,PESSOA M G.Biomarkers in hepatocellular carcinoma:Diagnosis,prognosis and treatment response assessment[J].Cells,2020,9(6):1370.
[13] 戴靖宜,蒋敬庭.肝细胞肝癌肿瘤标志物诊断的新进展[J].诊断学理论与实践,2023,22(5):486-493.
[14] 高越,万里新,曾庆,等.原发性肝癌患者介入治疗后血清LOXL4水平与复发的相关性分析[J].中西医结合肝病杂志,2023,33(8):698-701.
[15] ZHANG B,WAN H,MAIERWUFU M,et al.STAT3 ameliorates truncated tau-induced cognitive deficits[J].Neural Regen Res,2024,19(4):915-922.
[16] ZHAO L,PEI R,DING Y,et al.LOXL4 shuttled by tumor cells-derived extracellular vesicles promotes immune escape in hepatocellular carcinoma by activating the STAT1/PD-L1 Axis[J].J Immunother,2024,47(2):64-76.
[17] 李彬,朱泓,黄照能,等.赖氨酰氧化酶样蛋白3在人类恶性肿瘤发生、发展中的研究进展[J].临床与实验病理学杂志,2022,38(8):966-970.
[18] 张振奇,贺莉.弥散加权成像联合动态对比增强磁共振成像在肝细胞肝癌患者肝动脉化疗栓塞术后肿瘤活性检测中的应用价值[J].陕西医学杂志,2024,53(6):773-776,781.
[19] WU C Y,YIN K Z,ZHANG Y,et al.2,3,7,8-Tetrachlorodibenzo-p-dioxin promotes proliferation of astrocyte cells via the Akt/STAT3/Cyclin D1 pathway[J].Biomed Environ Sci,2019,32(4):281-290.
[20] LUO F,LU F T,QIU M Z,et al.Gemcitabine and APG-1252,a novel small molecule inhibitor of BCL-2/BCL-XL,display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.[J].Cell Death & Disease,2021,12(8):772.
[21] 张泽信,侯立朝.程序性细胞死亡因子4在肿瘤及炎症中的交叉作用研究进展[J].陕西医学杂志,2014,43(7):918-919.
[22] 李浩,邱磊,马泽龙,等.STAT3通路在肿瘤相关成纤维细胞调节肿瘤微环境中的作用[J].中国细胞生物学学报,2022,44(12):2345-2353.
[23] 王江涛,戴滋瀛,缪延栋,等.碳离子(12C 6+)抑制JAK2/STAT3通路促进肺癌中CD8+T细胞浸润的研究[J].中华放射肿瘤学杂志,2022,31(9):823-827.
[24] 程晓范,朱胡太龙,刘灵,等.STAT3信号在炎症性肠病及结肠炎相关结直肠癌发生发展中的作用和相关药物研究进展[J].药学学报,2022,57(8):2253-2261.
[25] 叶颖,杨娇,吴士臣.增强CT与磁共振成像在透明细胞型肝癌诊断中的对比研究[J].肝脏,2023,28(10):1179-1181,1190.

相似文献/References:

[1]齐洪武,乔民,刘岩松,等.下丘脑神经元错构瘤临床研究进展*[J].陕西医学杂志,2019,(1):135.
[2]王成均,侯 洪,曾幸萍,等.磁共振T2WI直方图在腰椎间盘退变中的应用价值研究*[J].陕西医学杂志,2019,(3):330.
　WANG Chengjun,HOU Hong,ZENG Xingping,et al.Value of T2WI histogram analysis in assessing lumbar intervertebral disc degeneration[J].,2019,(10):330.
[3]冯金艳,邱丽华.MRI检查对颈动脉粥样硬化斑块的诊断价值研究*[J].陕西医学杂志,2019,(4):467.
　FENG Jinyan,QIU Lihua..Diagnostic value of MRI examination for carotid atherosclerotic plaques[J].,2019,(10):467.
[4]柴茂林,马党捐.磁共振功能成像在脑胶质瘤诊断中的应用价值*[J].陕西医学杂志,2019,(5):603.
　CHAI Maolin,MA Dangjuan..The value of magnetic resonance imaging in glioma[J].,2019,(10):603.
[5]李齐云,马东东 ,张珍珍.磁共振成像在评价肝癌射频消融术疗效中的应用及其相应影像学特征分析[J].陕西医学杂志,2019,(7):916.
[6]张力召,魏光辉.右美托咪定滴鼻联合七氟醚吸入对磁共振成像检查婴幼儿镇静作用的研究*[J].陕西医学杂志,2020,49(1):93.
[7]陈张敏,商佳欢,魏鹏飞,等.体素内不相干运动技术在椎体良恶性压缩性骨折鉴别中的临床价值研究*[J].陕西医学杂志,2020,49(9):1085.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.008]
　CHEN Zhangmin,SHANG Jiahuan,WEI Pengfei,et al.Clinical value of IVIM technique in differential diagnosis of benign and malignant vertebral compression fracture[J].,2020,49(10):1085.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.008]

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基础研究计划项目(2023-JC-QN-0825)
更新日期/Last Update: 2024-10-08